Refractory Graves' disease
Conditions
Interventions
Control group:Control group (anti-hyperthyroidism): 8 weeks of anti-hyperthyroidism drugs and ß receptor blockers to improve the patients thyroid function to a normal FT4 level.
Experimental group:Study group (thyroid microwave ablation therapy): 8 weeks of anti-hyperthyroidism drugs and ß receptor blockers to improve the patients thyroid function to a normal FT4 level.
Sponsors
The Third Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Meet the diagnostic criteria for Graves' disease, including elevated FT4 levels, suppressed TSH levels, positive Trab results, and clinically detectable diffuse goiter; 2.A history of Graves' disease for 3 years, with continued use of antithyroid drugs or at least one recurrence of the disease; 3.Patients who refused surgery or RAI treatment; 4.Patients aged 18 to 65 years.
Exclusion criteria
Exclusion criteria: 1.Poor general condition, such as severe organic diseases involving the heart, liver, kidney, or other systems, or the presence of terminal malignant or wasting diseases; 2.Female patients with plans for pregnancy in the past year or during pregnancy; 3.Retrosternal thyroid or the majority of the thyroid gland located behind the sternum; 4.Unilateral vocal cord dysfunction on laryngoscopy; 5.Severe coagulopathy, neutropenia, or positive ANCA; 6.Malignant exophthalmos; 7.Adolescent patients; 8.Hyperthyroid patients with significant tracheal compression requiring urgent decompression; 9.Patients with psychiatric disorders or those unable to comply with treatment and follow-up; 10.Other conditions deemed inappropriate for participation by the investigator, such as participants who are unlikely to adhere to the protocol or have severe physiological or psychological conditions that may affect the efficacy or safety of the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate; | — |
Countries
China
Contacts
Public ContactLi Renyuan
The Third Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed